Search

Displaying results 8941 - 8950 of 10000 in total
  1. Drug

    GsMtx-4

    go.drugbank.com/drugs/DB17861
    Investigational

    GsMtx-4 is a peptide found in tarantula venom that inhibits mechanosensitive ion channel (MSC) activity.

  2. Drug

    DS-2325a

    go.drugbank.com/drugs/DB18134
    Investigational

    DS-2325a is an inhibitor of kallikrein 5 under development for the treatment of Netherton Syndrome.

  3. Drug

    LB-P8

    go.drugbank.com/drugs/DB18535
    Investigational

    LB-P8 is an investigational live biotherapeutic product consisting of a single bacterial strain (_Leuconostoc citreum_).

  4. Drug

    Sasanlimab

    go.drugbank.com/drugs/DB18849
    Investigational

    Sasanlimab is under investigation in clinical trial NCT06218069 (Immuno-pet Imaging Responses Administered Immune Checkpoint Inhibitor).

  5. Drug

    PEV3A

    go.drugbank.com/drugs/DB05144
    Investigational

    PEV3A is a prophylactic malaria vaccine that acts against various stages of the disease. It is a two-component vaccine that contains the virosome formulated peptide mimetics PEV301 and PEV302. The two synthetic peptide vaccine components...

  6. Drug

    MB07811

    go.drugbank.com/drugs/DB05192
    Investigational

    MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower serum cholesterol and triglycerides. MB07811, a small molecule that is administered orally, has been extensively studied preclinically ...

  7. Drug

    Flovagatran

    go.drugbank.com/drugs/DB05714
    Experimental

  8. Drug

    LCP-AtorFen

    go.drugbank.com/drugs/DB05769
    Investigational

    LCP-AtorFen is a fixed-dose combination therapy for the treatment of high cholesterol levels combining atorvastatin (the active ingredient of Lipitor®) and the lowest dose of fenofibrate without food effect. LCP-AtorFen is designed to be...

  9. Drug

    CVT-6883

    go.drugbank.com/drugs/DB05936
    Experimental

    CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics is investigating for the potential treatment of asthma and other conditions related to inflammation and fibrosis.

  10. Drug

    Amitifadine

    go.drugbank.com/drugs/DB05964
    Investigational